ProCE Banner Activity

Interim Phase II Results From AG221-AML-005: Enasidenib + Azacitidine vs Azacitidine Alone in Newly Diagnosed AML With IDH2 Mutations

Slideset Download
Conference Coverage
Combination enasidenib plus azacitidine improved ORR and CR rates vs azacitidine alone in patients with newly diagnosed AML with IDH2 mutations who were ineligible for intensive chemotherapy.

Released: December 17, 2019

Expiration: December 15, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company